tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Biogen (BIIB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNYResearch Report) and Biogen (BIIBResearch Report) with bullish sentiments.

Alnylam Pharma (ALNY)

Needham analyst Joseph Stringer reiterated a Buy rating on Alnylam Pharma today and set a price target of $205.00. The company’s shares closed last Thursday at $153.94.

According to TipRanks.com, Stringer is ranked 0 out of 5 stars with an average return of -19.4% and a 24.8% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Phathom Pharmaceuticals, and Rhythm Pharmaceuticals.

Currently, the analyst consensus on Alnylam Pharma is a Strong Buy with an average price target of $210.20, implying a 41.9% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $208.00 price target.

See the top stocks recommended by analysts >>

Biogen (BIIB)

Needham analyst Ami Fadia maintained a Buy rating on Biogen today and set a price target of $290.00. The company’s shares closed last Thursday at $224.47, close to its 52-week low of $212.56.

According to TipRanks.com, Fadia is a 1-star analyst with an average return of -1.6% and a 45.4% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Intra-Cellular Therapies, and ACADIA Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $264.78 average price target, implying a 18.0% upside from current levels. In a report issued on February 4, Cowen & Co. also maintained a Buy rating on the stock with a $285.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALNY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed